NAD Tries To Steer Syntratech From Diabetes Claims, Rx Comparisons
This article was originally published in The Tan Sheet
Executive Summary
Syntratech says claims it made for its Syntra-5 herbal product do not imply it conducted comparisons with Rx drugs, but the firm may risk a run-in with FDA or the Federal Trade Commission with some of its claims